Cowen analyst, Eric Schmidt, reiterated his Outperform rating on shares of Amgen (NASDAQ: AMGN) after the draft 2017 LDL treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE